Navigation Links
Safety in Biological Technology

Next Safety Releases Advanced Respirator for Infectious Diseases

JEFFERSON, N.C., Aug. 5 /PRNewswire/ -- Next Safety, Inc. (NSI) announces advanced respirators that give people more confidence to go to work in a pandemic environment. Next Safety is releasing for sale to the public respirator products the company developed for the bird flu influenza A ...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced new six month safety and efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor an...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with he...

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

ROCKVILLE, Md. , July 13 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system infection due to West Nile Viru...

EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements

The European Food Safety Authority (EFSA) concludes no safety concerns for the use of chromium picolinate in food supplements, in response to Nutrition 21's Application to market Chromax(R) chromium picolinate in Europe . PURCHASE, N.Y., June 30 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. ...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic...

iCardiac Selected for Multiple Cardiac Safety Studies

Continues Market Leadership in Highly Automated QT(sm) Evaluation and Helps Sponsors Avoid False Positives Rochester, NY (PRWEB) June 15, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced ...

Assessment of safety and efficacy of human embryonic stem cell therapy

Worcester, MA June 11, 2009 (EurekAlert)--Advanced Cell Technology, Inc. (OTC:ACTC.PK) and its collaborators at OHSU reported today the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for hu...

Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients

SEATTLE, June 11 /PRNewswire/ -- Neurim Pharmaceuticals ( http://www.neurim.com ) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results w...

Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation

WASHINGTON, May 22 /PRNewswire/ -- The Partnership for Clear Health Communication at the National Patient Safety Foundation today announced the recipients of the prestigious Pfizer Health Literacy in Advancing Patient Safety Award. Honored for their innovative and influential efforts in the Health...

Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22

MEDIA ALERT WASHINGTON, May 18 /PRNewswire-USNewswire/ -- Focusing on critical healthcare reform efforts and best practices essential to reducing preventable adverse events, and responding to President Obama's bold principles for change, influential leaders will gather at the National Patient...

CellGard ES NU-480 Class II Biological Safety Cabinet Now Available

The CellGard Energy Saver (ES) NU-480 Biological Safety Cabinet (BSC) is now available in North America. The CellGard ES is a Class II, Type A2 BSC which features NuAire's exclusive TouchLink LCD Control Center, a DC-ECM motor, sloped window, and the longest filter life in its class. Learn more.....

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

BOTHELL, WA and VANCOUVER, May 14 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced the release of two abstracts to be presented during oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts are now availab...

Avoiding False Positives Key Priority in Cardiac Safety Studies

Pharmaceutical Companies Recognizing Risks with Traditional Cardiac Safety Approaches Rochester, NY (PRWEB) May 4, 2009 -- iCardiac Technologies, Inc., a leading innovator in advanced cardiac safety biomarkers and automated QT analysis, today announced the results of it...

Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman

Next Safety, Inc. has developed the most effective pulmonary nicotine delivery device to help people quit smoking JEFFERSON, N.C., April 27 /PRNewswire/ -- Matthew P. Bars, MS, CTTS, has joined Next Safety, Inc. (NSI) as chairman. In his smoking cessation work, he has appeared on the NBC Toda...

BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01...

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries -- DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL ...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAEST...

Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750

CALGARY, April 6 /PRNewswire/ - Orcrist Bio Inc. (ORC) a biotechnology company developing stem cell-mobilizing pharmaceuticals, announced today the approval of its Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers, by the European Competent Authority in ...

iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company

Study Includes iCardiac's Highly Automated QT(sm) Solution Rochester, New York (PRWEB) April 1, 2009 -- iCardiac Technologies announced today that its advanced cardiac safety biomarkers were used successfully in a clinical study to model the effect of a serious disease ...

NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week

BOSTON, March 3 /PRNewswire/ -- In a concerted, nationwide effort to encourage and strengthen collaboration between patients, families, and their healthcare providers -- and create a powerful team for improved patient safety -- the National Patient Safety Foundation will introduce the Universa...

USDA Boosts Food Safety Research with Purchase of Waters ACQUITY TQD System

UPLC/Tandem Quadrupole Mass Spectrometry System Intended for Veterinary Drug Residue Analysis of Poultry and Livestock MILFORD, Mass., Feb. 27 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT ) announced today that the United States Department of Agriculture's Agricultural Research S...

Hospira Advances Patient Safety With New GemStar(R) SP Infusion System

- Safety Protocol Integration Enhances Market-Leading GemStar Medication Management Pump - LAKE FOREST, Ill., Feb. 25 /PRNewswire-FirstCall/ --Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the introduction of the GemSt...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium - SOU...

Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750

CALGARY, Feb. 9 /PRNewswire/ - Orcrist Bio Inc. (ORC) a biotech company developing stem cell-mobilizing pharmaceuticals, announced today that it has filed with the European Competent Authority in Seville, Spain, a Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male v...

ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections

FREDERICK, Md., Feb. 9 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of their small molecule inhibitor of HIV-1 at the 16th CROI meeting held this week in Montreal. The presentation highlighted the advanced development of ImQuest's lead HI...

ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services

PHILADELPHIA, Jan. 30 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), and Integrium, LLC announced today their alliance to provide integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring centralized core laboratory services to clinical trial sponsors and ma...

NewCardio Joins the Cardiac Safety Research Consortium

NewCardio to work closely with regulators, academia and pharmaceutical industry in the development of advanced ECG cardiac safety tools SANTA CLARA, Calif., Jan. 22 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced...

Patient Safety in Challenging Economic Times is Focus of NPSF Annual Congress on May 20-22

BOSTON, Jan. 13 /PRNewswire/ -- Responding to the increased risk to patient safety in an economic downturn, the National Patient Safety Foundation has announced that the 2009 NPSF Patient Safety Congress will directly address this issue through an extensive program of educational sessions desi...

The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates

LANSING, Mich., Jan. 12 /PRNewswire/ -- The Risk Management and Patient Safety Institute (RM&PSI) today announced its winter and spring 2009 audio program calendar. The RM&PSI ( http://www.rmpsi.com ), a subsidiary of FinCor Holdings Inc. ( http://www.fincorholdings.com ), is a nation...

BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)

Additional Safety Data Could Drive Product Adoption in High-Growth Cell Therapy Market BOTHELL, Wash., Dec. 16 /PRNewswire-FirstCall/ --BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media p...

Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD

ATLANTA, Dec. 11 /PRNewswire/ -- Alimera Sciences Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and eff...

Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure

SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. R...

Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411

DURHAM, N.C., Dec. 4 /PRNewswire/ -- Parion Sciences, Inc. today announced that its partner, Gilead Sciences (Nasdaq: GILD ), has initiated a Phase I clinical trial of GS9411 in healthy volunteers to evaluate the safety and tolerability of the investigational compound. GS9411 is designed to inc...

Bioenergy D-Ribose Achieves Highest Safety Standard

MINNEAPOLIS, Nov. 20 /PRNewswire/ -- Integrative life science company Bioenergy, Inc. has achieved GRAS status (generally recognized as safe) from the U.S. Food and Drug Administration (FDA) for its core energy nutrient D-ribose, a naturally occurring monosaccharide the body uses to stimulate the ...

B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit

Shawn O'Connell Discusses Implementation Issues and Recommendations BETHLEHEM, Pa., Nov. 12 /PRNewswire/ -- Shawn O'Connell, MS, RN, Director of Clinical Value Marketing, Infusion Systems Division and Helen Chang, PharmD, Director of Pharmacy, Clinical Services for B. Braun Medical Inc. (B. B...

Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial

AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects ATLANTA, Nov. 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the...

Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure

SAN MATEO‚ Calif.‚ Nov. 10 /PRNewswire/ -- Corthera Inc. today announced that an interim analysis of top-line data from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, international study, showed favorable efficacy and safety for relaxin, the compan...

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

- Updated Preliminary Results Presented at 20th EORTC-NCI-AACR Symposium - SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced positive incremental data from it...

Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

- Updated Results Presented at 20th EORTC-NCI-AACR Symposium - SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced positive incremental data from its ongo...
Other Tags
(Date:10/22/2014)... Oct. 20, 2014 The Nano-Bio Manufacturing Consortium ... Force Research Laboratory (AFRL), has chosen a project proposed ... the University of Arizona College of Medicine – ... AzCIM project,s goal is to assess different sweat collection ... volumes of sweat under a variety of human-body conditions, ...
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... available in German . ... every day in order to reproduce? And why are there ... of the latest issue of the research journal Molecular ... biologist Steven Ramm from Bielefeld University Bielefeld has compiled this ... unusual for a female to copulate with several males in ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2
(Date:10/25/2014)... (HealthDay News) -- Not getting the right amount of ... new study suggests. Those who sleep less or ... night may be more prone to developing the chronic ... The study authors concluded that duration and quality of ... with inflammatory bowel diseases. "Both short and long ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... increased risks for certain cancers, one might think that high-risk ... a new study suggests that, at least with colon cancer, ... genes doubled their risk of colon cancer were no more ... "It didn,t make any difference, not at all," said study ...
(Date:10/22/2014)... 22, 2014 At a time when ... parents and athletes at all levels, the UPMC ... the current discussion where two powerful messages are lost: ... that result in full recoveries every day. , In ... in fact and research, UPMC and the Concussion Program ...
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
Other Contents